KR20140097106A - 4-브로모-n-(이미다졸리딘-2-일리덴)-1h-벤즈이미다졸-5-아민을 포함하는, 망막 질병들 치료용 약제학적 조성물들 - Google Patents

4-브로모-n-(이미다졸리딘-2-일리덴)-1h-벤즈이미다졸-5-아민을 포함하는, 망막 질병들 치료용 약제학적 조성물들 Download PDF

Info

Publication number
KR20140097106A
KR20140097106A KR1020147004520A KR20147004520A KR20140097106A KR 20140097106 A KR20140097106 A KR 20140097106A KR 1020147004520 A KR1020147004520 A KR 1020147004520A KR 20147004520 A KR20147004520 A KR 20147004520A KR 20140097106 A KR20140097106 A KR 20140097106A
Authority
KR
South Korea
Prior art keywords
retinal
ylidene
bromo
imidazolidin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147004520A
Other languages
English (en)
Korean (ko)
Inventor
모하메드 아이. 디바스
존 이. 도넬로
다니엘 더블유. 길
제임스 에이. 버크
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20140097106A publication Critical patent/KR20140097106A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147004520A 2011-07-22 2012-07-22 4-브로모-n-(이미다졸리딘-2-일리덴)-1h-벤즈이미다졸-5-아민을 포함하는, 망막 질병들 치료용 약제학적 조성물들 Withdrawn KR20140097106A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161510743P 2011-07-22 2011-07-22
US201161510536P 2011-07-22 2011-07-22
US61/510,536 2011-07-22
US61/510,743 2011-07-22
PCT/US2012/047777 WO2013016252A1 (en) 2011-07-22 2012-07-22 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases

Publications (1)

Publication Number Publication Date
KR20140097106A true KR20140097106A (ko) 2014-08-06

Family

ID=46599017

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147004520A Withdrawn KR20140097106A (ko) 2011-07-22 2012-07-22 4-브로모-n-(이미다졸리딘-2-일리덴)-1h-벤즈이미다졸-5-아민을 포함하는, 망막 질병들 치료용 약제학적 조성물들

Country Status (12)

Country Link
US (1) US20130046003A1 (cg-RX-API-DMAC7.html)
EP (1) EP2734202A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014521648A (cg-RX-API-DMAC7.html)
KR (1) KR20140097106A (cg-RX-API-DMAC7.html)
CN (1) CN103826631A (cg-RX-API-DMAC7.html)
AU (1) AU2012287062A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014001538A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842756A1 (cg-RX-API-DMAC7.html)
IL (1) IL230582A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014000870A (cg-RX-API-DMAC7.html)
RU (1) RU2014106328A (cg-RX-API-DMAC7.html)
WO (1) WO2013016252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
AU2020454040B2 (en) 2020-06-19 2025-03-06 Endogena Therapeutics, Inc. New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
US6066675A (en) 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
MX2012008516A (es) * 2010-01-21 2012-10-15 Allergan Inc Agonista alfa-2 adrenergico que tiene larga duracion de efecto de baja presion intraocular.

Also Published As

Publication number Publication date
EP2734202A1 (en) 2014-05-28
JP2014521648A (ja) 2014-08-28
CA2842756A1 (en) 2013-01-31
IL230582A0 (en) 2014-03-31
CN103826631A (zh) 2014-05-28
BR112014001538A2 (pt) 2017-02-14
RU2014106328A (ru) 2015-08-27
US20130046003A1 (en) 2013-02-21
WO2013016252A1 (en) 2013-01-31
MX2014000870A (es) 2014-06-23
AU2012287062A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
CN109996814B (zh) 多激酶抑制剂及在眼部纤维化中的用途
JP2005524626A (ja) 眼疾患を治療するための方法
JP2009001591A (ja) 緑内障治療用のデプレニル化合物
US20130046003A1 (en) Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
JP2007517885A (ja) 眼に投与するためのメマンチンおよびポリアニオン性ポリマーを含む組成物
US20220062255A1 (en) Treatment of neurodegenerative eye disease using pridopidine
JP2013501794A (ja) 目の疾患を治療するためのイソチオゾール
US20070112032A1 (en) Prevention and/or reduction of photoreceptor degeneration with retinoids
CA2475338C (en) Treatment of ophthalmic disorders using urea and urea derivatives
WO2001056606A1 (en) Remedies for ophthalmic diseases
CA2817505C (en) Pharmaceutical formulation having neuroprotective activity
Akyol et al. Ciliary body toxicity of cyclosporin A and octreotide acetate in rabbit eyes: a comparison with mitomycin C and 5-fluorouracil
JP2002154985A (ja) 眼疾患治療剤
JP2008507588A (ja) 眼の病態を処置する方法
KR20140097485A (ko) 망막 보호용의 7-(1h-이미다졸-4-일메틸)-5,6,7,8-테트라하이드로-퀴놀린을 포함하는 약제학적 조성물
HK40000005B (en) Compositions and methods of using nintedanib for improving glaucoma surgery success

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid